Esperion announces plans for new research on lead development candidates

Esperion (ESPR) announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis, PSC. These candidates are novel allosteric inhibitors of ATP citrate lyase, ACLY, a key metabolic enzyme with emerging relevance in hepatic inflammation and fibrosis. “We are leveraging our deep expertise in ACLY biology to expand our portfolio beyond NEXLETOL/NEXLIZET and to address the urgent needs of patients living with PSC,” said Sheldon Koenig, Chief Executive Officer at Esperion. “Our lead candidates, including ESP-1336, are promising, potential first-in-class allosteric ACLY inhibitors, well-characterized with significant preclinical data, and represent a natural extension of our metabolic franchise. PSC is a rare and progressive liver disease with no approved therapies proven to slow or halt its progression. Our next-generation ACLY inhibitor discovery program was purpose-built to improve potency, selectivity, and guide indication and patient population selection through data-driven innovation.”